Incyte Genomics (INCY) Misses Q2 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.04 --0%
Financial Fact:
Provision for income taxes: 1.43M
Today's EPS Names:
TRI, CRVL, DD, More
Financial Fact:
Provision for income taxes: 1.43M
Today's EPS Names:
TRI, CRVL, DD, More
Join SI Premium – FREE
Incyte Genomics (NASDAQ: INCY) reported Q2 EPS of ($0.41), $0.05 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $19.17 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $108 at Bernstein SocGen Group
- Incyte (INCY) PT Lowered to $116 at Morgan Stanley
- Incyte (INCY) PT Lowered to $127 at Wells Fargo
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
